brodalumab   Click here for help

GtoPdb Ligand ID: 7540

Synonyms: AMG-827 | AMG827 | Kyntheum® | Lumicef® | Siliq®
Approved drug Immunopharmacology Ligand
brodalumab is an approved drug (Japan (2016), FDA (2017), EMA (2017))
Compound class: Antibody
Comment: Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It targets the interleukin 17 receptor A (IL17RA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
Immunopharmacology Comments
Treatment with brodalumab carries the warning that the drug is associated with suicidal ideation and behaviour [5]. The mechanistic explanation for an increased suicide risk is unknown, and this risk factor has not been associated with other approved drugs that target the same pathway (e.g. secukinumab and ixekizumab which both target the IL-17 ligand rather than the IL-17 receptor).
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Approved therapeutic for plaque psoriasis.
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Clinical candidate for asthma.
Psoriatic arthritis Disease Ontology: DOID:9008
Clinical candidate for PsA.